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Background: On March 2020, World Health Organization (WHO) declared COVID-19 to be a
pandemic disease. Interactions between allergy-related inflammatory and psychiatric disorders
including depression, anxiety, and post-traumatic stress disorder (PTSD) have been documented.
Therefore, those who have pre-existing allergic conditions may have an increased psychiatric re-
action to the stresses of the COVID-19 pandemic.
Objective: Identify the psychological impact of COVID-19 in patients with allergic diseases and
determine if these individuals have a greater risk of presenting with post-traumatic stress disorder
(PTSD).
Methods: It is a cross-sectional, survey-based study designed to assess the degree of symptoms
of depression and the risk of PTSD using the Patient Health Questionnaire (PHQ-9) and the Impact
of Event Scale–Revised (IES-R), respectively, in allergic patients.
Results: A total of 4106 surveys were evaluated; 1656 (40.3%) were patients with allergic disease,
and 2450 (59.7%) were non-allergic (control) individuals. Of those with allergies, 76.6% had res-
piratory allergic disease including asthma and allergic rhinitis. Individuals with allergic disease
reported higher scores regarding symptoms of PTSD on the IES-R scale (p ¼ 0.052, OR 1.24 CI
0.99–1.55) as well as a higher depression risk score in the PHQ-9 questionnaire (mean 6.82 vs.
5.28) p ¼ 0.000 z ¼ 8.76.
The allergy group presented a higher score in the IES-R questionnaire (mean 25.42 vs. 20.59),
being more susceptible to presenting PTSD (p ¼ 0.000, z ¼ 7.774).
The individuals with allergic conditions were further divided into subgroups of those with respi-
ratory allergies such as allergic rhinitis and asthma vs those with non-respiratory allergies such as
drug and food allergy, urticaria and atopic dermatitis. This subgroup analysis compares respiratory
versus non-respiratory allergic patients, with similar results on the IES-R (mean 25.87 vs 23.9)
p ¼ 0.0124, z ¼ 1.539. There was no significant difference on intrusion (p ¼ 0.061, z ¼ 1.873)
and avoidance (p ¼ 0.767, z ¼ 0.297), but in the hyperarousal subscale, patients with respiratory
allergy had higher scores (mean 1.15 vs. 0.99) p ¼ 0.013 z ¼ 2.486.
Conclusions: Psychological consequences such as depression and reported PTSD are present
during the COVID-19 pandemic causing an impact particularly in individuals with allergic diseases.ional Center of Allergy and Clinical Immunology, University Hospital
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Keywords: Allergic, COVID-19, Psychologic, ImpactBACKGROUND comorbidities reported for patients with COVID-In January 2020, World Health Organization
(WHO) declared the outbreak of a new coronavirus
disease, COVID-19, to be a Public Health Emer-
gency of International Concern, and in March
2020, WHO made the assessment that COVID-19
was a pandemic disease. WHO and public health
authorities around the world are acting to contain
the COVID-19 outbreak.1 Across the world,
reactions to this unforeseen pandemic have
impacted lives in a number of ways, to include
lockdown and shelter in place orders which have
led to job loss and economic devastation for
some. The health and economic uncertainty,
coupled with the sheer numbers of countries and
people involved, have made the COVID-19 crisis
the largest global disruption since World War II.
This has been overwhelming for some, creating
difficulty in coping with life during the pandemic.
SARS-CoV-2, the virus that causes COVID-19, is
highly contagious, capableof causingseverepneu-
monia, acute respiratory distress syndrome, and
death,particularlyinvulnerablepopulationssuchas
those with respiratory diseases.2,3 In patients with
allergicdiseases it is recommendedtomonitor their
allergy and asthma symptoms, as there may be
overlapping symptoms which may lead to a







infection;6however, thedataarenot yet conclusive,
and allergic patients may experience a
misperception of their allergic disease against
COVID-19 leading to additional psychological
changes.7
Asthma and other chronic respiratory diseases
appear to be underrepresented in the19, observing a similar pattern as that reported in
patients with SARS (2.4%); with this in mind,
changes in the treatment of chronic respiratory
diseases should not be considered, including
chronic obstructive pulmonary disease (COPD)
and asthma.8 With a great part of the world in
quarantine, levels of anxiety have begun to
surge, leading patients to identify, and in some
cases, seek medical attention for symptoms that
otherwise might not have caused concern.9
Other psychological reactions that appear in
pandemics include emotional distress, maladap-
tive behaviors, and defensive responses. People
who have greater susceptibility to psychological
problems are particularly vulnerable.10
Interactions between allergy-related inflamma-
tory and psychiatric disorders, such as depres-
sion,11 anxiety, bipolar disorder, and
schizophrenia have been previously
documented.12 More specifically, asthma, rhinitis,
or atopic dermatitis and the combination of all 3
of these allergic diseases, have been associated
with a higher risk of psychiatric disorders.13 A
higher incidence of allergic diseases has been
seen in patients with post-traumatic stress disor-
der (PTSD), and it has been suggested that im-
mune activation is a contributor to clinical status.14
The prevalence of PTSD among direct victims of
disasters such as natural, technological, or
human-made (terrorism) ranges between 30%
and 40%, while the range of PTSD rates in the
general population is the lowest and expected to
be between 5% and 10%.15 Immunologic
morbidity has been reported in patients with
history of PTSD including a lower number of
lymphocytes, T cells, NK cell activity, and total
amounts of IFN-g and IL-4.16 Other immune
alterations such as increased levels of
inflammatory cytokines including IL-1, IL-6, and
TNF-a have also been studied.14 This time of
pandemic crisis is generating stress throughout
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to identify the psychological impact of COVID-19
in patients with allergic diseases and determine if
these individuals have a greater risk of presenting
with PTSD.METHODS
Surveys were sent out by allergists, to adults
over 18 years old, via a Google Forms link, and
shared through different social media platforms as
well as by telephone in the case of patients who
attended the allergy and immunology clinic. There
were no other limitations regarding the population
surveyed. Digital informed consent was provided
by all survey participants prior to their enrollment.
A copy of the survey will be available as an online
supplement. Participants were allowed to deny the
survey if they did not accept digital informed
consent. The survey was anonymous, and confi-
dentiality of the information was assured.
The study is a cross-sectional, survey-based,
stratified study with demographic data and mental
health measurements from 4106 participants
collected from April 1 to 15, 2020 during a period
in which our country, Mexico, was entering the
uncertainty of phase 3 of the pandemic response
due to COVID-19 and most of America was under
quarantine.
The survey contained 2 questionnaires that
assessed the degree of symptoms of depression,
anxiety, and the risk of post-traumatic stress dis-
order (PTSD), using the 9-item Patient Health
Questionnaire (PHQ-9) and the 22-item Impact of
Event Scale–Revised (IES-R), respectively. Multivar-
iable logistic regression analysis was performed to
identify factors associated with mental health
outcomes.
The 9-item PHQ test has a range of responses
from 0 to 27 and is used to assess the severity of
symptoms of depression. Scores are interpreted as
follows: none-minimal (0–4), mild (5–9), moderate
(10–14), moderately severe (15–20), and severe
(20–27) depression. The 22 item IES-S test has a
range of 0–88 and tests the severity of symptoms of
distress. Scores are interpreted as follows: signifi-
cant clinical concern (24–32), probable diagnosis
of PTSD, and reflecting long-term suppression of
immune system functioning (39 and above).16,19With the introduction of the DSM-IV, the IES was
updated to include 3 subscales: intrusion, avoid-
ance, and hyperarousal.19 These categories were
based on values established in the literature. The
cutoff score for detecting symptoms of major
depression and distress were 10 and 24,
respectively. In the DSM-5, PTSD is included in a
new category, Trauma- and Stressor-Related Dis-
orders. The scales were used based on the DSM-IV.
Participants who had scores greater than the cutoff
threshold were characterized as having severe
symptoms.17–19
Demographic data was self-reported by the
participants, including gender (male or female),
age, geographic location (Mexico, United States,
and Latin American countries), marital status (sin-
gle, married, divorced, living with a couple,
widow), educational level (elementary school,
middle school, high school, undergraduate, post-
graduate and others), place of residence (house or
apartment with or without patio), and patient's re-
ported allergic disease (allergic rhinitis, asthma,
atopic dermatitis, urticaria, food allergy, drug al-
lergy). Medication intake specifically regarding al-
lergy and psychopharmacologic agents was not
inquired.
Data analysis was performed using SPSS statis-
tical software version 25.0 (IBM Corp). The signifi-
cance level was set at a ¼ 0.05, and all tests were
2-tailed. The ranked data, which were derived from
the counts of each level for symptoms of depres-
sion, and distress, are presented as numbers and
percentages. The nonparametric Mann-Whitney U
test and Kruskal-Wallis test were applied to
compare the severity of each symptom between 2
or more groups. To determine potential risk factors
for symptoms of depression, and distress in par-
ticipants, multivariable logistic regression analysis
was performed, and the associations between risk
factors and outcomes are presented as odds ratios
(ORs) and 95% CIs, after adjustment for con-
founders, including gender, age, geographic
location, marital status, educational level, place of
residence, and presence of allergic disease.RESULTS
A total of 4106 surveys were evaluated; the
majority were female 2991 (72.9%). Patients were
divided into those with allergic disease 1656
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non-allergic 2450 (59.7%). The average ages were
35.2 and 36.7, respectively.
48.6% were married, Mexican nationality 96.2%
(3949), 79.9% live in a house with a patio and


































Allergic Rhinitis and asthma:
Allergic Rhinitis, asthma and atopic dermatitis:
Allergic rhinitis, asthma, atopic dermatitis and
food allergy:
Other:
Table 1. Characteristics of allergy and control groupA total of 1656 patients with allergic disease
were included in the study: 76.6% (1268 re-
spondents) had respiratory allergic disease
(asthma and allergic rhinitis) and 23.4% (388 re-
spondents) had non-respiratory allergic disease
(atopic dermatitis, urticaria, food allergy and drug
allergy).Allergy group Control group





404 (24.4%) 705 (28.8%)
1249 (75.4) 1742 (71.1%)
3 (0.2%) 3 (0.1%)
1597 (96.4%) 2352 (96%)
59 (3.6%) 98 (4%)
698 (42.1%) 880 (36%)
760 (45.9%) 1235 (50.4%)
70 (4.2%) 118 (4.8%)
113 (6.8%) 185 (7.5%)
15 (1%) 32 (1.3%)
10 (0.6%) 10 (0.4%)
31 (1.9%) 89 (3.6%)
132 (8%) 312 (12.7%)
907 (54.7%) 1384 (56.5%)
546 (33%) 592 (24.2%)
30 (1.8%) 63 (2.6%)
122 (7.4%) 133 (5.4%)
124 (7.5%) 180 (7.3%)
1280 (77.3%) 2001 (81.7%)
111 (6.7%) 114 (4.7%)












1 AC 2 AC 3 AC 4 AC 5 AC 6 AC


































Fig. 2 Respiratory and non-respiratory allergy
Volume 14, No. 3, March 2021 5Of these patients, 64% (1055 individuals) pre-
sented 1 allergic condition (AC) and 23% (386 in-
dividuals) had 2 reported allergic conditions
(Fig. 1).
In total, 1656 patients declared to suffer from
2535 allergic diseases, of which 57.2% (1449) were
respiratory allergic diseases, and 42.8% (1086)
were non respiratory allergies (Fig. 2).
The allergy group presented a higher score in
the IES-R questionnaire (mean 25.42 vs. 20.59),
being more susceptible to presenting PTSD
(p ¼ 0.000, z ¼ 7.774). They also presented
higher scores on the IES-R subscales: intrusion
(mean 1.2 vs. 0.96), avoidance (mean 1.15 vs. 0.99)
and hyperarousal (mean 1.12 vs. 0.84), being sta-
tistically significant p ¼ 0.000 z ¼ 7.856,
p ¼ 0.000 z ¼ 6.027, and p ¼ 0.000 z ¼ 8.563
respectively.
This group also had a higher depression risk
score in the PHQ-9 questionnaire (mean 6.82 vs.
5.28) p ¼ 0.000 z ¼ 8.76. Even so, both groups
presented data suggesting mild depression
symptoms (Table 2).
The group with respiratory allergy also had
higher IES-R scores (mean 25.87 vs 21.05)
p ¼ 0.000 z ¼ 7.176. In the IES-R subscales, res-
piratory allergic patients were at higher risk:
intrusion (mean 1.22 vs 0.98) p ¼ 0.000
z ¼ 7.481, avoidance (mean 1.15 vs 1.01)
p ¼ 0.000 z ¼ 5.045, and hyperarousal (mean
1.15 vs 0.86) p ¼ 0.000 z ¼ 8.379.
In addition, in the respiratory allergy group a
higher score on the PHQ-9 depression scale (mean
7.14 vs. 5.35) p ¼ 0.000, z ¼ 9.43 was evidenced
(Table 3).
Finally, respiratory versus non-respiratory
allergic patients were compared, with similar re-
sults (mean 25.87 vs 23.9) p ¼ 0.0124, z ¼ 1.539.
There was no significant difference on intrusion
(p ¼ 0.061, z ¼ 1.873) and avoidance (p ¼ 0.767,
z ¼ 0.297), but in the hyperarousal subscale,
patients with respiratory allergy had higher scores
(mean 1.15 vs. 0.99) p ¼ 0.013 z ¼ 2.486.
Patients in the respiratory allergy group also had
a higher risk of depression symptoms in the PHQ-9
questionnaire (mean 7.14 vs. 5.7) p ¼ 0.000z ¼ 4.006 compared to allergic patients without
respiratory pathologies (Table 4).
There is an increased risk of having an allergic
disease and presenting symptoms of PTSD on the
IES-R scale (p ¼ 0.052, OR 1.24 CI 0.99–1.55). Also
being female and having PTSD symptoms on the
IES-R scale (p ¼ 0.000, OR 1.41, CI 1.18–1.68), as
well as being between 18 and 59 years old
(p ¼ 0.001, OR 1.87, CI 1.27–2.76), although in our
Respiratory Allergy Control Group Respiratory Allergy Control Group
IES-R IES-R PHQ-9 PHQ-9
N¼ 1268 2838 1268 2838
Mean 25.871 21.056 7.140 5.357
Median 21.5 17 6 4
IQR 29 24 8.25 7
Z 7.196 9.43
P-value 0.000 0.000
Intrusion Avoidance Hyperarousal Intrusion Avoidance Hyperarousal
Mean 1.22 1.15 1.15 0.98 1.01 0.86
Median 1 1 0.83 0.75 0.88 0.67
IQR 1.25 1.37 1.5 1.12 1.12 1.16
Z 7.481 5.045 8.379
P-value 0.000 0.000 0.000
Table 3. Respiratory allergy group vs. Control group
Allergy Group Control Group Allergy Group Control Group
IES-R IES-R PHQ-9 PHQ-9
n¼ 1656 2450 1656 2450
Mean 25.422 20.597 6.824 5.289
Median 21 16 5 4
IQR 28 23 8 7
Z 7.774 8.76
P-value 0.000 0.000
Intrusion Avoidance Hyperarousal Intrusion Avoidance Hyperarousal
Mean 1.2 1.15 1.12 0.96 0.99 0.84
Median 1 1 0.83 0.75 0.88 0.5
IQR 1.28 1.37 1.38 1 1.12 1.16
Z 7.856 6.027 8.563
P-value 0.000 0.000 0.000
Table 2. Allergy vs. Control group










IES-R IES-R PHQ-9 PHQ-9
N¼ 1268 388 1268 388
Mean 25.871 23.9 7.140 5.7
Median 21.5 20 6 4
IQR 29 28 8.25 8
Z 1.539 4.006
P-value 0.124 0.000
Intrusion Avoidance Hyperarousal Intrusion Avoidance Hyperarousal
Mean 1.22 1.15 1.15 1.12 1.14 0.99
Median 1 1 0.83 0.88 1.00 0.75
IQR 1.37 1.25 1.33 1.25 1.37 1.50
Z 1.873 0.297 2.486
P-value 0.061 0.767 0.013
Table 4. Respiratory allergy vs. Non-respiratory allergy Group
Volume 14, No. 3, March 2021 7population the majority is in this age range. The
allergic group that presented an educational level
of undergraduate presented higher scores in the
IES-R questionnaire (p ¼ 0.002, OR 1.00, CI 1.00–
1.01). There was no significant difference in the
place of residence (p ¼ 0.251, OR 0.995, IC 0.98–
1.00), marital status (p ¼ 0.971, OR 1.00, IC 0.91–
1.09) and if they had their allergic disease under
control (p ¼ 0.821, OR 1.00, IC 0.97–1.00).
The group with allergic respiratory disease has
an increased risk of developing PTSD (p ¼ 0000,
OR 1.38, CI 1.15–1.66), the female gender
(p ¼ 0.000, OR 1.66, CI 1.43–1.93), and being in
the age group between 18 and 59 years
(p ¼ 0.000, OR 3.46, CI 2.46–4.85).
The undergraduate group has a higher score in
the IES-R questionnaire (p ¼ 0.001, OR 1.00, IC
1.00–1.01). There was no difference in the place of
residence (p ¼ 0.406, OR 0.99, IC 0.99–1.00),
marital status (p ¼ 0.157, OR 1.00, IC 0.99–1.00),
and having control of allergic respiratory disease
(p ¼ 0.625, OR 1.00, CI 0.99–1.00).
The group with allergic disease had a higher risk
of developing depression symptoms on the PHQ-9
scale (p ¼ 0.001, OR 1.37, CI 1.13–1.65), as well as
the female population had a higher risk of
depression (p ¼ 0.000, OR 1.65, CI 1.43–1.91), andhaving an age of 18–59 years (p ¼ 0.000, OR 3.97,
CI 2.86–5.51). It was also evidenced that the single
marital status had a higher risk of depression in
both men and women (p ¼ 0.000, OR 1.2, CI 1.11–
1.29). There was no higher risk depending on the
place of residence (p ¼ 0.590, OR 1.00, CI 0.99–
1.00), educational level (p ¼ 0.219, OR 1.00, CI
0.99–1.00) and the control of their allergic disease
(p ¼ 0.309)., OR 1.00, CI 0.99–1.00).
Finally, patients with allergic respiratory disease
have a higher risk of presenting depression
symptoms (p ¼ 0.000, OR 1.60, CI 1.34–1.92), also
the female gender (p ¼ 0.000, OR 1.58, CI 1.37–
1.83), and being under 60 years old is the risk
factor with the highest association in presenting
depression symptoms (p ¼ 0.000, OR 4.37, CI
3.16–6.05). There is no statistically significant rela-
tionship depending on the place of residence
(p ¼ 0.764, OR 1.00, CI 0.99–1.00), the educational
level (p ¼ 0.153, OR 1.00, CI 0.99–1.00), marital
status (p ¼ 0.519, OR 1.00, CI 0.99–1.00), and the
control of allergic respiratory disease (p ¼ 0.843,
OR 1.00, CI 0.99–1.00).DISCUSSION
Prior research has reported a wide spectrum of
psychological impact that outbreaks or worldwide
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vidual level, it can trigger new psychiatric symp-
toms in people with no diagnosed mental illness,
aggravate the condition of those with pre-existing
mental illness, and cause stress for the caregivers
that are affected. Regardless of exposure, people
may present with fear and anxiety of becoming ill
or dying, triggering a mental breakdown.20
Psychiatric morbidities have been found
including depression, anxiety, and posttraumatic
stress disorder symptoms.21,22
Our study revealed that during this period of
quarantine due to COVID-19, the psychological
impact in patients with allergic diseases was
greater compared to individuals without allergy.
Allergic patients had a higher risk of depression
symptoms measured with the PHQ-9 scale and of
reported PTSD evaluated with the IES-R scale
which is measured within 2 weeks of exposure to
event, impacting specifically in the intrusion,
avoidance, and hyperarousal section. Individuals
with respiratory allergy such as asthma and rhinitis
were particularly vulnerable to a higher PHQ-9 and
PTSD scale. Previous studies have demonstrated
an association between PTSD and an increased
incidence of allergic and autoimmune diseases.23
Huang et al showed a significant link between
PTSD and asthma,24 where underlying alterations
in psychophysiological, neuroendocrine, and
neurobiological systems have been implicated.25
Glenk et al reported that allergic individuals
showed higher scores regarding emotion
suppression, had increased pre-stress concentra-
tions of plasma oxytocin, and demonstrated a
stronger salivary cortisol response to stress than
healthy people.26
In the group of allergic patients from 18 to 59
years of age, there was a higher risk of depression
and PTSD, being predominant in the female pop-
ulation surveyed. These results contrast with other
studies that have reported older adults as a high-
risk group of PTSDs due to several factors in
adapting such as an increased sense of insecurity
and vulnerability; a loss of sense of control and
predictability; and a need to reaffirm familiar re-
lationships, attachments, and routines.27 Kelly et al
reported that seasonal allergies were positively
associated with odds of mild depression and
PTSD. Asthma was not significantly associated
with any psychiatric disorder.28Similar to our results, depression as well as
anxiety and reported PTSD have been found to
affect women more than men, peaking at the age
of 20–40 years, possibly due to underlying bio-
logical predispositions such as hormonal fluctua-
tion related to the menstrual cycle.27 Also,
depression was more prevalent in unmarried or
widowed individuals, as previously reported.29
In our results, the level of patient's allergic dis-
ease control did not influence the risk of devel-
oping depression or affect the scores in the PHQ-9
questionnaire. Depression may modify the degree
of severity with which symptoms are perceived by
patients and in consequence modify the level of
asthma control, while poorly controlled asthma
could lead to depression.30,31 According to Ferro
et al, adolescents with asthma are associated with
an increased risk of clinically relevant symptoms of
depression; on the other hand food allergy is
associated with an increased risk of clinically
relevant symptoms of anxiety.32
Atopic dermatitis is associated with high levels
of social withdrawal, stigmatization, anxiety, and
depression among patients and their caregivers.
Stress caused by atopic dermatitis can make the
symptoms of the disease worse.33 Individuals with
chronic urticaria may develop PTSD symptoms
which influence their psychological well-being
through using different levels of emotional sup-
pression, especially suppressing depression. The
levels depend on the severity of PTSD symptoms
and whether they experienced interpersonal
traumas.34
During pandemics such as the one being
experienced all over the world, a worry for health,
changes in everyday life, job loss, economic ordeal
and family conflicts may occur and lead to
depression disorders. Previous studies measured
the impact of COVID-19 early on. Zhang et al used
the Chinese version 9-item General Health Ques-
tionnaire (GHQ-9) and 7-item Generalized Anxiety
Disorder (GAD-7) scale to evaluate the prevalence
and severity of psychological distress in patients
recovered from COVID-19 infection, individuals
under quarantine, and the public in general. They
found severe depression symptoms in the general
population compared to our study in which in-
dividuals with allergic diseases showed mild
symptoms.35 Cultural differences and state of the
Volume 14, No. 3, March 2021 9pandemic, as well as public perception of the virus,
may be some of the causes for the differences.
Based on their results, they recommended
prompt intervention measures that should be
taken to alleviate the psychological issues
faced.35 Vanaken et al published, after the
execution of this study, the use of IES-COVID19
which proved to be a reliable and valid measure
for investigating stress symptoms related to
trauma regarding intrusion and avoidance due to
short- and long-term impact of the COVID-19
pandemic. The IES-COVID19 may be a resource-
ful instrument in assessing individual changes in
traumatic stress symptoms over time.36
To the best of our knowledge this is one of the
first studies that evaluates the psychologic effect of
COVID-19 in allergic patients. However, a limita-
tion to this study is that there are no pre-
measurements; therefore, it may not be well
defined if the reactivity to the environmental
stressor is causal. As specialists in the allergy field,
it is imperative that we recognize the psychological
burden that the pandemic has on our patients
which may be a limiting factor in overcoming the
crisis. We conclude that psychological conse-
quences such as depression, anxiety, and PTSD are
present during the COVID-19 pandemic and cause
an impact in individuals with allergic diseases that
may persist even after the pandemic has ended. If
we acknowledge this impact and how it affects
people during the pandemic, we are better able to
implement interventions, follow up, and contribute
to the entire well-being of our patients. Due to a
worldwide increase in allergic diseases, the
mechanisms involved in stress experiences as well
as best practice management strategies should be
studied in-depth.SUPPORTING INFORMATION LEGENDS
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Patients With Allergic Diseases.
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